Gene therapy for spinal muscular atrophy

被引：0
作者：
Gowda, Vasantha Lakshmi [1 ,3 ]
Jungbluth, Heinz [1 ,2 ]
Wraige, Elizabeth [1 ]
机构：
[1] Evelina London Childrens Hosp, Dept Paediat Neurol, London, England
[2] Kings Coll London, Randall Div Cell & Mol Biophys, Muscle Signalling Sect, London, England
[3] Evelina London Childrens Hosp, Paediat Neurosci, London SE1 7EH, England
来源：
ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION | 2023年 / 108卷 / 05期
关键词：
Neurology; Paediatrics; Pharmacology; Therapeutics;
D O I：
10.1136/archdischild-2023-325359
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
[No abstract available]
引用
收藏
页码：347 / 350
页数：4
相关论文
共 50 条
  • [31] Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis
    Gavriilaki, Maria
    Moschou, Maria
    Papaliagkas, Vasileios
    Notas, Konstantinos
    Chatzikyriakou, Evangelia
    Papagiannopoulos, Sotirios
    Arnaoutoglou, Marianthi
    Kimiskidis, Vasilios K.
    NEUROTHERAPEUTICS, 2022, 19 (02) : 464 - 475
  • [32] Biomarkers of therapeutic efficacy in adolescents and adults with 5q spinal muscular atrophy: a systematic review
    Gavriilaki, Maria
    Papaliagkas, Vasileios
    Stamperna, Alexandra
    Moschou, Maria
    Notas, Konstantinos
    Papagiannopoulos, Sotirios
    Arnaoutoglou, Marianthi
    Kimiskidis, Vasilios K.
    ACTA NEUROLOGICA BELGICA, 2023, 123 (05) : 1735 - 1745
  • [33] Risdiplam in Adult Patients With 5q Spinal Muscular Atrophy: A Single-Center Longitudinal Study
    Gavriilaki, Maria
    Moschou, Maria
    Pagiantza, Maria
    Arnaoutoglou, Marianthi
    Kimiskidis, Vasilios
    MUSCLE & NERVE, 2025, 71 (03) : 384 - 391
  • [34] Spinal muscular atrophy in an upper-middle-income nation before the advent of reimbursed disease-modifying therapies
    Sakpichaisakul, Kullasate
    Katanyuwong, Kamornwan
    Intusoma, Utcharee
    Paprad, Tanitnun
    Suwanpakdee, Piradee
    Khongkhatithum, Chaiyos
    Sanmaneechai, Oranee
    BMJ PAEDIATRICS OPEN, 2024, 8 (01)
  • [35] Spinal presentations in children with type 1 spinal muscular atrophy on nusinersen treatment across the SMA-REACH UK network: a retrospective national observational study
    Abbott, Lianne
    Main, Marion
    Wolfe, Amy
    Rohwer, Annemarie
    Baranello, Giovanni
    Munot, Pinki
    Manzur, Adnan
    Muntoni, Francesco
    Scoto, Mariacristina
    SMA REACH UK Network Physiotherapists
    BMJ OPEN, 2025, 15 (01):
  • [36] Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development
    Butchbach, Matthew E. R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (15)
  • [37] VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models
    Jeremiah Hadwen
    Duncan MacKenzie
    Fahad Shamim
    Kevin Mongeon
    Martin Holcik
    Alex MacKenzie
    Faraz Farooq
    Orphanet Journal of Rare Diseases, 9
  • [38] VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models
    Hadwen, Jeremiah
    MacKenzie, Duncan
    Shamim, Fahad
    Mongeon, Kevin
    Holcik, Martin
    MacKenzie, Alex
    Farooq, Faraz
    ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [39] The factorial survey as an approach to investigate clinical decision-making: examining influences on a clinician's decision to initiate life-sustaining clinical technology for a child with spinal muscular atrophy type 1
    Quirke, Mary Brigid
    Cassidy, Lorna
    Alexander, Denise
    Walsh, Cathal
    Hill, Katie
    Masterson, Kate
    Flynn, Nia
    Brenner, Maria
    FRONTIERS IN PEDIATRICS, 2023, 11
  • [40] Prospective approaches to gene therapy computational modeling - spotlight on viral gene therapy
    Choules, Mary P.
    Bonate, Peter L.
    Heo, Nakyo
    Weddell, Jared
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2024, 51 (05) : 399 - 416
12345